Dynavax Pharma (DVAX): רווח נקי למניה ב-12 החודשים האחרונים

Dynavax Technologies (DVAX) leads in the development of advanced vaccines and CpG 1018 platforms, investing in the fight against liver infections. Fundamental net income per share TTM demonstrates yield dynamics, with the indicator fixed at -0.38. An impeccable brand image is confirmed by physician trust in hepatitis B medications. A stable cash flow is ensured by strong demand for the flagship product.

The indicator calculates the ratio of net income to the total number of shares over a rolling year, measuring the actual efficiency of capital generation per share. Steady growth in the rolling earnings per share history confirms the transition of Dynavax Technologies (DVAX) from startup status to that of a reliable player, converting high confidence in hepatitis B vaccines into a sustainable financial result.